QuidelOrtho Valuation
Is 0A55 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0A55 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0A55 ($36.25) is trading below our estimate of fair value ($101.09)
Significantly Below Fair Value: 0A55 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0A55?
Key metric: As 0A55 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0A55's PS Ratio? | |
|---|---|
| PS Ratio | 0.9x |
| Sales | US$2.82b |
| Market Cap | US$2.43b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.8x |
| Enterprise Value/EBITDA | 8.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0A55's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.2x | ||
SN. Smith & Nephew | 1.9x | 5.0% | UK£8.4b |
NIOX NIOX Group | 6.5x | 12.1% | UK£253.1m |
CREO Creo Medical Group | 2.3x | -4.9% | UK£69.4m |
EKF EKF Diagnostics Holdings | 2.2x | 7.6% | UK£113.4m |
0A55 QuidelOrtho | 0.9x | 1.4% | US$2.4b |
Price-To-Sales vs Peers: 0A55 is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (3.2x).
Price to Sales Ratio vs Industry
How does 0A55's PS Ratio compare vs other companies in the GB Medical Equipment Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
SPEC INSPECS Group | 0.3x | 5.5% | US$73.06m |
YGEN Yourgene Health | 0.6x | n/a | US$20.48m |
IHC Inspiration Healthcare Group | 0.4x | 13.6% | US$17.80m |
SUN Surgical Innovations Group | 0.4x | n/a | US$6.47m |
| 4 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 0A55 is good value based on its Price-To-Sales Ratio (0.9x) compared to the UK Medical Equipment industry average (3.1x).
Price to Sales Ratio vs Fair Ratio
What is 0A55's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.9x |
| Fair PS Ratio | 1.6x |
Price-To-Sales vs Fair Ratio: 0A55 is good value based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$36.25 | US$51.50 +42.1% | 19.6% | US$64.00 | US$38.00 | n/a | 6 |
| Nov ’25 | US$39.03 | US$52.50 +34.5% | 17.9% | US$64.00 | US$38.00 | n/a | 6 |
| Oct ’25 | US$44.54 | US$52.50 +17.9% | 17.9% | US$64.00 | US$38.00 | n/a | 6 |
| Sep ’25 | US$43.92 | US$49.40 +12.5% | 22.1% | US$64.00 | US$38.00 | n/a | 5 |
| Aug ’25 | US$42.03 | US$49.40 +17.5% | 22.1% | US$64.00 | US$38.00 | n/a | 5 |
| Jul ’25 | US$33.92 | US$50.00 +47.4% | 21.7% | US$64.00 | US$37.00 | n/a | 5 |
| Jun ’25 | US$44.02 | US$51.40 +16.8% | 24.3% | US$68.00 | US$37.00 | n/a | 5 |
| May ’25 | US$39.93 | US$54.73 +37.1% | 27.2% | US$81.00 | US$37.00 | n/a | 6 |
| Apr ’25 | US$48.47 | US$58.80 +21.3% | 28.6% | US$81.00 | US$37.00 | n/a | 5 |
| Mar ’25 | US$45.90 | US$60.67 +32.2% | 26.3% | US$81.00 | US$37.00 | n/a | 6 |
| Feb ’25 | US$69.88 | US$99.33 +42.1% | 34.6% | US$158.00 | US$66.00 | n/a | 6 |
| Jan ’25 | US$74.50 | US$99.33 +33.3% | 34.6% | US$158.00 | US$66.00 | n/a | 6 |
| Dec ’24 | US$68.09 | US$104.83 +54.0% | 32.4% | US$158.00 | US$66.00 | n/a | 6 |
| Nov ’24 | US$59.95 | US$121.00 +101.8% | 22.7% | US$168.00 | US$85.00 | US$39.03 | 6 |
| Oct ’24 | n/a | US$121.00 0% | 22.7% | US$168.00 | US$85.00 | US$44.54 | 6 |
| Sep ’24 | US$83.79 | US$121.00 +44.4% | 22.7% | US$168.00 | US$85.00 | US$43.92 | 6 |
| Aug ’24 | US$86.79 | US$125.50 +44.6% | 21.4% | US$173.00 | US$91.00 | US$42.03 | 6 |
| Jul ’24 | US$83.33 | US$125.00 +50.0% | 21.4% | US$173.00 | US$91.00 | US$33.92 | 6 |
| Jun ’24 | US$85.60 | US$125.00 +46.0% | 21.4% | US$173.00 | US$91.00 | US$44.02 | 6 |
| May ’24 | US$89.15 | US$124.00 +39.1% | 22.0% | US$173.00 | US$87.00 | US$39.93 | 6 |
| Apr ’24 | US$90.02 | US$125.00 +38.9% | 22.1% | US$173.00 | US$87.00 | US$48.47 | 6 |
| Mar ’24 | US$88.31 | US$125.00 +41.5% | 22.1% | US$173.00 | US$87.00 | US$45.90 | 6 |
| Feb ’24 | US$86.22 | US$124.17 +44.0% | 22.0% | US$173.00 | US$93.00 | US$69.88 | 6 |
| Jan ’24 | US$84.85 | US$124.17 +46.3% | 22.0% | US$173.00 | US$93.00 | US$74.50 | 6 |
| Dec ’23 | US$90.48 | US$126.20 +39.5% | 39.2% | US$219.00 | US$90.00 | US$68.09 | 5 |
| Nov ’23 | US$88.76 | US$126.20 +42.2% | 39.3% | US$219.00 | US$86.00 | US$59.95 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Fagron
€1.4b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
0HNZ
€18.61
7D
-1.4%
1Y
6.7%
Centene
US$29.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$57.48
7D
-5.5%
1Y
-20.8%
Elevance Health
US$92.9b
Operates as a health benefits company in the United States.
0HG8
US$401.96
7D
-5.3%
1Y
-13.1%